跳至主要内容
临床试验/EUCTR2017-000230-62-Outside-EU/EEA
EUCTR2017-000230-62-Outside-EU/EEA进行中(未招募)1 期

A Phase III study of M071754 - A single-blind study in patients with infantile spasms.

Alfresa Pharma Corporation and Sanofi KK0 个研究点目标入组 12 人开始时间: 2017年4月24日最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients (aged >=4 weeks, <2 years) diagnosed with infantile spasms manifested by spasms and hypsarrhythmia on electroencephalography. Using classification of ILAE 1989
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 12
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Patients with concurrent severe liver/renal disease, cardiac disease, serious gastrointestinal disorder.
  • - Patients who received adrenocorticotropic hormone (ACTH) products or steroids within 4 weeks (28 days prior to the formal registration of this study.
  • - Patients previously or currently treated with vigabatrin.
  • - Patients who have concurrent or a history of ophthalmological complication in whom possible aggravation of the symptoms with vigabatrin.
  • - Patients with concomitant Lennox-Gastaut syndrome.

研究者

发起方
Alfresa Pharma Corporation and Sanofi KK

相似试验